vVARDIS Sets $18.00 IPO Price Below The $21.00–$24.00 Range It Marketed

The $175 million base offering comes in a slower IPO market, with recent biopharma debuts showing uneven returns.

Share
vVARDIS Sets $18.00 IPO Price Below The $21.00–$24.00 Range It Marketed

vVARDIS, a Swiss dental-technology company, priced its IPO at $18.00 per share Thursday, below the $21.00–$24.00 range marketed to investors. The offering is set to raise $175 million, according to the company's pricing announcement.

A Smaller Price For The Debut

The base deal covers 9,722,223 Class A shares. vVARDIS expects the stock to begin trading Friday on the New York Stock Exchange with the ticker VVVV.

Underwriters have a 30-day option to buy up to 1,458,333 additional Class A shares at the IPO price. Those shares are separate from the $175 million base offering.

Goldman Sachs and J.P. Morgan headed the underwriting group, joined by William Blair, UBS Investment Bank and Deutsche Bank Securities. The Securities and Exchange Commission declared the offering's registration effective Thursday.

Curodont Meets A Slower IPO Market

Based in Zug, Switzerland, vVARDIS sells Curodont dental products. Co-founders Haley Abivardi and Goly Abivardi are its co-chief executives, according to Thursday's amended IPO filing.

The listing comes as IPO activity has fallen. Renaissance Capital counted 121 priced IPOs through Tuesday, down 36% from 2025.

Biopharma accounted for seven of October's nine new listings, putting healthcare businesses at the center of that month's activity. But only two of those seven stocks traded above their offering prices as of Tuesday.

The vVARDIS offering is expected to close on or about Monday.

Sources